鼠疫耶尔森氏菌VcrV基因在大肠杆菌中的高效表达

将测序后的鼠疫耶尔森氏菌（Yersinia pestis)LcrV基因重组质粒pGEM－T／ypV酶切,克隆于原核表达载体pBV220,构建成pBV/ypV表达质粒,转化大肠杆菌DH5α,进行PCR及酶切鉴定,筛选阳性克隆,进行温控诱导表达,SDS－PAGE检测表达产物,在相对分子质量38000处有－表达条带,经薄层扫描分析目的蛋白带占全菌蛋白的38．4％以上,主要以可溶形式存在。     

hrpZ基因在大肠杆菌中的高效表达与活性检测

PCR扩增hrpZ基因片段,克隆到pGEM-T载体中,经EcoRI／Xho1酶切、连接将hrpZ基因插人大肠杆菌表达载体pET32b（＋）硫氧还蛋白下游,构建重组表达质粒pET-hrpZ,再将其转化至E．coli BL21（DE3）中,经筛选得到阳性克隆子,IPTG诱导表达HrpZ蛋白。SDS-PAGE显示,目的蛋白在重组菌株中得到了可溶性高效表达。该重组蛋白分子量为55．8kD,与理论值大小相符。采用叶片穿刺法,融合蛋白具有诱导烟草过敏反应的生物功能。     

人工会成柞蚕杀菌肽D基因的克隆及在大肠杆菌中的表达

以质粒pWR450为载体,克隆了人工合成的柞蚕杀菌肽D基因(122bp),构建的重组子pWR450-Cec转化大肠杆菌JM103、用限制性内切酶酶切鉴定。产物经SDS-聚丙烯酰胺凝胶电泳,结果显示可表达杀菌肽-β-gal融合蛋白。     

沙门菌外膜蛋白D的原核表达及多克隆抗体制备

目的:在大肠杆菌中表达沙门菌外膜蛋白(OMP)D,纯化后制备兔抗OMPD抗体。方法:用PCR方法从鼠伤寒沙门菌中扩增出ompD基因,并插入融合表达载体pET-28a(+)的多克隆位点,构建重组表达质粒pET28a(+)-ompD;以重组质粒转化大肠杆菌BL21(DE3),筛选阳性重组菌株,经IPTG诱导目的蛋白表达,在变性条件下对目的蛋白进行亲和层析纯化;以表达的OMPD蛋白免疫家兔,制备抗OMPD的多克隆抗体并进行鉴定。结果:扩增了ompD基因,测序证实正确后亚克隆于表达载体pET-28a(+)中,经PCR筛选和酶切鉴定获得阳性克隆,经诱导在大肠杆菌中表达出相对分子质量为40×103的目的蛋白并进行纯化;纯化的OMPD免疫家兔后,能有效地刺激特异性抗体的产生,抗血清的效价达到1∶10000以上,且具有良好的特异性。结论:构建ompD基因的原核表达载体,并在大肠杆菌中获得高效表达;制备出兔抗OMPD抗体,效价及特异性均良好,为进一步制备肠黏膜高亲和力疫苗奠定了基础。     

△12-脂肪酸脱氢酶基因在大肠杆菌中的表达

把高山被孢霉(Mortierella alpina)和深黄被孢霉(Monierella isabellina)的△^12-脂肪酸脱氢酶基因亚克隆到大肠杆菌表达载体pET21a中,获得重组表达载体pMACL12和pMICL12,并用氯化钙方法将重组表达载体转化到大肠杆菌B121(DE3)中。筛选阳性克隆进行培养,然后分离其细胞膜蛋白,并构建体外表达体系,同时加入外源性底物油酸进行表达。经气相色谱(GC)分析表明,分别有17．87％和17．60％的油酸转化为亚油酸。     

GST/ AEP 融合蛋白原核表达载体的构建、表达及鉴定

目的：为进一步研究抗癫痫肽（And—epilepsy peptide,AEP）的抗痫机制及筛选其相关作用蛋白,进行GST／AEP融合蛋白原核表达载体的构建及融合蛋白的表达。方法：通过PCR基因扩增对AEP基因进行扩增,并将其克隆于谷胱甘肽-S-转移酶（GST）融合蛋白表达质粒pGEX-4T-1中,经酶切、序列鉴定分析后,用该重组质粒转化大肠杆菌B121（DE3）,经IPTG诱导获得表达,并采用Western Blot进行检测。结果：成功构建了AEP原核表达载体,并在大肠杆菌B121中获得表达。结论：成功构建了GST／AEP原核表达载体,并表达了GST／AEP融合蛋白。     

胸腺素a1／干扰素a-2b融合基因表达载体的构建与表达

通过PCR人工合成模板的方法获得牛m1基因,与含,IFNa-2b基因的pAG-IFN重组质粒,构建％1／IFNar-2b融合基因重组质粒pUCl8-Ta1／IFN,经序列分析证实,融合基因m1和,INFa-2b与GenBank登录基因的序列一致性分别为100％和98．5％,仅IFNa-2b有两处碱基发生无义突变．再将融合基因亚克隆入pBV220,构建融合表达载体pBV220-Ta1／IFN,转化到EcoliM15经IPTG诱导,实现了Ta1-1FNa-2b融合蛋白的高表达,约占菌体总蛋白的24．5％,为包涵体形式．这为研制Ta1—IFNa-2b双重活性的融合蛋白奠定了基础．     

恶性疟P190抗原基因的表达及免疫学研究

克隆了我国海南省FCCl／HN株P190抗原三肽重复区基因,定名为P190TR。该基因片段经DNA序列分析鉴定后连接到改建的pGEx一2T表达载体BamHⅠ和xbaⅠ位点中,经鉴定的重组质粒转化感受态JM109(DE3)大肠杆菌进行表达。结果显示：该基因得到高效融合表达．经一步亲和纯化后就取得高纯度的重组蛋白。用纯化的表达蛋白免疫动物亦产生P190TR特异性抗体。     

PTK重组质粒的构建与表达

目的构建并表达出PTK重组蛋白,以鉴定酪氨酸蛋白激酶(PTK)的活性,筛选酪氨酸激酶的抑制剂。方法从PTK重组克隆载体上切下目的基因片段Abl-PTK使其连接到表达载体pGEX4T-2上,转化大肠杆菌DH5a,筛选鉴定出正确的转化子。转化菌株经IPTG诱导后进行表达并进行SDS-PAGE分析。结果经酶切和诱导表达鉴定,重组质粒pGEX4T-2-PTK构建成功,并高效表达了58KD的GST-PTK融合蛋白。结论PTK基因被成功地重组至融合蛋白表达载体中,并在大肠杆菌中获得高效表达。该研究为进一步纯化、鉴定PTK的活性,筛选PTK的抑制剂奠定了基础。     

流感病毒nsl基因的克隆及其原核表达载体的构建

为了解H5N1亚型流感病毒株的nsl基因特性及其规模制备NSl蛋白,首先将病毒在鸡胚中传代,从收获的尿囊液中提取RNA,采用RT-PCR技术扩增流感病毒全长ns基因。测序显示H5N1亚型流感病毒NSlcDNA全长678bp,编码225个氨基酸。BLAST分析表明,Qa/ST／852,01(H5N1)病毒株nsl基因与近年来从华南地区分离的禽H5N1毒株的nsl基因有很高的同源性。之后采用PCR方法扩增nsl基因的cDNA片段,将其克隆到pGEX-4T-3载体中,与谷胱甘肽巯基转移酶(GST)基因融合,构建重组质粒pGEX-4T-3／NSlcDNA,转化大肠杆菌BL21(DE3)并进行诱导表达。SDS,PAGE和凝胶扫描分析,GS~NSl融合蛋白在大肠杆菌中获得了高效表达,并且以可溶形式存在,重组融合蛋白的表达量占菌体总蛋白的28．5％,表达产物经亲和层析纯化后蛋白质纯度达96％以上。经免疫印记证实重组融合蛋白可以被GST特异性抗体所识别。该表达载体的构建为获得大量NSl蛋白进行功能研究及抗体制备提供了基础。     

HCV复合多表位抗原基因表达及免疫原性的研究

分类号Ｑ７８１文献标识码Ａ文章编号０００１６２０９（１９９９）０３０２６８７１丙型肝炎是常见的传染病之一,易于慢性化及发展为肝硬化,且与肝癌的发生关系密切,目前尚无理想的防治手段。国内外对丙型肝炎疫苗的研究仍处于克隆表达ＨＣＶ部分基因产物或合成…     

HCV/HBV复合抗原基因的克隆、表达及免疫应答研究

为探讨ＨＣＶ／ＨＢＶ 复合疫苗的可行性,将合成的丙型肝炎病毒（ＨＣＶ）复合多表位抗原基因ＰＣＸ与ＨＢｓＡｇ 基因连接成ＰＣＸＳ基因,与β－半乳糖苷酶（ＧＺ）基因融合后在大肠杆菌及减毒鼠伤寒沙门氏菌中获得表达．目的蛋白ＧＺ－ＰＣＸＳ可被抗－ＨＢｓ 及抗－ＨＣＶ 抗体所特异识别．ＧＺ－ＰＣＸＳ抗原皮下注射免疫ＩＣＲ小鼠后,诱发了较高水平的抗－ＧＺ－ＰＣＸＳＩｇＧ反应．构建的重组减毒鼠伤寒沙门氏菌ＳＬ３２６１（ｐＷＲ／ＰＣＸＳ）口服免疫小鼠后,诱发了高水平的ＣＤ８＋ Ｔ细胞增殖反应及抗ＧＺ－ＰＣＸＳＩｇＧ反应．所有免疫小鼠均未见明显的毒副作用．该研究揭示,ＨＣＶ／ＨＢＶ 复合抗原可诱发特异性体液免疫及细胞免疫应答,而活菌苗口服可能是理想的免疫途径,为ＨＣＶ／ＨＢＶ 双价疫苗研究提供了一定的理论及实验依据．     

人乳头瘤病毒16型湖北株E7基因的克隆和高效表达

利用基因克隆技术,将ＨＰＶ１６湖北株完整的Ｅ７基因克隆到含乳糖操纵子的表达载体ｐＷＲ５９０１上,经限制性酶切分析获得重组质粒ｐＷＨＢＥ７。ｐＷＨＢＥ７转化大肠杆菌后表达产生分子量为７０ｋＤ的融合蛋白ｌａｃＥ７,该蛋白在免疫印迹实验中可被标准Ｅ７单抗识别。经ＩＰＴＧ诱导后,Ｅ７融合蛋白产量可达细菌总蛋白含量的３０％以上。利用ｌａｃＥ７蛋白在细菌胞浆中形成包含体的性质,简便地提取并纯化了该蛋白质。结果为从免疫学角度探讨ＨＰＶ１６与宫颈癌的关系以及ＨＰＶ疫苗的研制打下基础。     

Expression and activation of an esterase from Pseudomonas aeruginosa 1001 in Escherichia coli

An expression vector was constructed to overproduce a maltose binding protein (MBP)-esterase fusion protein in Escherichia coli. Soluble fusion protein was separated by centrifugation after cell disruption. The fusion protein was partially purified with amylose resin. The higher concentration of fusion protein (above 2 mg/ml) did not show any activity but about 0.3 mg/ml of fusion protein had the highest activity (142 U/ml). It is due to the difficulty of contact between substrate and active site of enzyme in compact form at high concentration. The fusion protein over-expressed could not be separated into MBP and esterase by the action of protease ‘Factor Xa’. The esterase could be cleaved from MBP fusion protein by the treatment of SDS with the Factor Xa, and the resulting esterase activity was increased to 34% after cleavage.     

Expression of human parathyroid hormone-(1-84) in Escherichia coli as a factor X-cleavable fusion protein

Recombinant human parathyroid hormone (hPTH)-(1-84) was obtained from Escherichia coli using a cleavable fusion protein strategy. The fusion protein contains residues 1-138 of human growth hormone as the amino-terminal region and residues 1-84 of hPTH as the carboxyl-terminal region. A 7-residue linker containing the recognition/cleavage sequence of the site-specific blood coagulation protease activated factor X (factor Xa) joins the two regions. Intact hPTH-(1-84) is released from this fusion protein by cleavage in vitro with factor Xa. The fusion protein was produced at a high level and formed inclusion bodies which allowed it to be easily purified by low speed centrifugation, with a yield of approximately 50 mg/liter of culture. After factor Xa cleavage and high performance liquid chromatography purification, highly purified hPTH was obtained, with a final yield of 1.5-3 mg/liter. Physical and biological characterization of the purified hormone demonstrated that it was intact and active hPTH-(1-84).     

High-level expression and rapid purification of rare-codon genes from hyperthermophilic archaea by the GST gene fusion system

In this study, we compared two gene fusion expression strategies using two rare codon genes (Ssh10b and MtGrxM) from archaea as a model system. Both genes can be highly expressed as N- or C-terminal fusion partners to GST or the intein/chitin-binding tag. However, the fusion protein with intein tag could not be cleaved, even under stringent conditions, possibly due to steric hindrance, thus preventing further purification. In contrast, the GST fusion system could increase protein expression level and the corresponding fusion protein could be easily cleaved by thrombin. After binding to glutathione sepharose, the fusion protein was cleaved on column, and a roughly purified protein fraction was eluted. This fraction was purified by heating at 80 degrees C for 10 min, followed by centrifugation. The correct total mass and N-terminal primary structure were confirmed by mass spectrometry and Edman degradation. Both constructs were used for in vitro expression, and similar results were obtained, indicating higher expression levels of the GST tag vs. intein/chitin tag. Taken together, our results suggest that the GST fusion system can be used as a considerable alternative to synthetic genes for the expression of rare codon genes. The affinity chromatography purification followed by a heating step is an efficient and convenient method for thermostable protein purification.     

Synthesis of an immunopathogenic fusion protein derived from a bovine interphotoreceptor retinoid-binding protein cDNA clone

We have extended the cDNA sequence of bovine interphotoreceptor retinoid-binding protein (IRBP) and subcloned one of the sequenced cDNA fragments into an expression vector. The nucleotide (nt) sequences of four bovine IRBP cDNA clones have been determined. These sequences when assembled cover the 3' proximal 3629 nt of the IRBP mRNA and encode the C-terminal 551 amino acids (aa) of IRBP. This cDNA sequence validates the intron: exon boundaries predicted from the gene. A 2-kb EcoRI insert from lambda IRBP2, one of the clones sequenced, encoding the C-terminal 136 aa of IRBP was subcloned into the expression vector pWR590-1. Escherichia coli carrying this plasmid construction, pXS590-IRBP, produced a fusion protein containing 583 N-terminal aa of beta-galactosidase, three linker aa residues, 136 C-terminal aa of IRBP and possibly a number of additional C-terminal residues due to suppressed termination. This 86-kDa fusion protein, purified by detergent/chaotrope extraction followed by reverse-phase high-performance liquid chromatography, cross-reacted with anti-bovine IRBP on Western blots. This protein induced an experimental autoimmune uveo-retinitis and experimental autoimmune pinealitis in Lewis rats indistinguishable from that induced by authentic bovine IRBP. Thus, it is evident that biological activity of this region of IRBP, as manifested by immuno-pathogenicity, is retained by the fusion protein.     

Recombinant production and purification of novel antisense antimicrobial peptide in Escherichia coli

A fusion protein was genetically engineered that contains an antimicrobial peptide, designated P2, at its carboxy terminus and bovine prochymosin at its amino terminus. Bovine prochymosin was chosen as the fusion partner because of its complete insolubility in Escherichia coli, a property utilized to protect the cells from the toxic effects of the antimicrobial peptide. This fusion protein was purified by centrifugation as an insoluble inclusion body. A methionine linker between prochymosin and the P2 peptide enabled P2 to be released by digestion with cyanogen bromide. Cation exchange HPLC followed by reversed-phase HPLC were used to purify the P2 peptide. The recombinant P2 peptide's molecular mass was confirmed by mass spectrometry to within 0.1% of the theoretical value (2480.9 Da), and the antimicrobial activity of the purified recombinant P2 against E. coli D31 was determined to be identical to that of the chemically synthesized peptide (minimal inhibitory concentration of 5 mg/mL). Although the yield of the fusion protein after expression by the cells was high (16% of the total cell protein), the percentage recovery of the P2 peptide in the inclusion bodies was relatively low, which appears to be due to losses in the cyanogen bromide digestion step.     

Chemical synthesis, molecular cloning, and expression of the gene coding for the Trichosanthes trypsin inhibitor--a squash family inhibitor.

The gene coding for a Trichosanthes trypsin inhibitor analog (Ala-6-TTI) in which methionine at position 6 was replaced by alanine was synthesized chemically. The synthetic gene was cloned into plasmid pWR590-1 and expressed in Escherichia coli as a fusion protein composed of beta-galactosidase fragment of 590 amino acid residues and (Ala-6)-TTI, with methionine as a connecting residue. After cyanogen bromide cleavage and reduction of the fusion protein, followed by refolding with trypsin-Sepharose 4B as a matrix and affinity chromatography on the immobilized enzyme, the fully active (Ala-6)-TTI was obtained. The trypsin inhibitory activity and amino acid composition of the recombinant (Ala-6)-TTI were consistent with those of the natural one. The (Ala-6)-TTI gene was also cloned into the secretion expression vector, pVT102U/alpha, in Saccharomyces cerevisiae. In order to make the reading frame of the gene compatible with the vector, a nucleotide was inserted into the (Ala-6)-TTI gene via site-directed mutagenesis. The secreted (Ala-6)-TTI was purified and found to be correctly processed at the junction between the alpha-factor leader peptide and (Ala-6)-TTI downstream. Of the two expression systems, the latter is more advantageous in the high yield (greater than 2 mg/liter), easy purification and needlessness of disulfide refolding.     

人胰岛素A,B链基因的合成,克隆及其在大肠杆菌中的表达

Human insulin A and B chain genes were designed and synthesized by using a rapid and simple method. The synthesized A and B chain genes were cloned separately. The expression (plasmids) pWR 590-HIA and pWR 590-HIB were constructed, and the two plasmids can direct the synthesis of the approximately 590 amino acid-long truncated beta-galactosidases fused to human insulin A or B chains. The fused A or B chain proteins were isolated from the fermented cells and cleaved with BrCN. The resulting mixtures were sulfonated and the sulfonated A and B chains were purified. Human insulin was obtained by using an A and B chain combination method.